1Long JL, et al. (2008) Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS. 22: 489-496.

2D'Souza G, et al. (2014) Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr 65: 603-610.

3Brickman, C. and J.M. Palefsky (2015) Cancer in the HIV-Infected Host: Epidemiology and Pathogenesis in the Antiretroviral Era. Curr HIV/AIDS Rep 12:388-396.

4Pacheco, Y.M., et al. (2015) Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort. Antiviral Res 117: 69-74.

5Bruyand M, et al. (2009) Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 49: 1109-1116.

6Neuhaus J, et al. (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 201: 1788-1795.

7Borges AH, et al. (2013) Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS 27:1433-1441.

8Romani BS, Engelbrecht RH (2010) Glashoff, Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J Gen Virol 91:1-12.

9Kim RH, et al. (2008) HIV-1 Tat enhances replicative potential of human oral keratinocytes harboring HPV-16 genome. Int J Oncol 334: 777-782.